Literature DB >> 8176929

Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients.

N Karimine1, S Nanbara, S Arinaga, T Asoh, H Ueo, T Akiyoshi.   

Abstract

Lymphokine-activated killer (LAK) cell activity of peripheral blood mononuclear cells (PBM), spleen cells (SPC), regional lymph node cells (LNC), and tumor-infiltrating lymphocytes (TIL), induced by activation with interleukin 2 (IL 2) for 4 days, was evaluated in patients with gastric carcinoma. TIL exhibited the lowest LAK activity and the cytotoxicity of LNC was significantly lower than that of either PBM or SPC. There was no difference between PBM and SPC. Then, there were significant correlations of LAK activity among PBM, SPC, and LNC, whereas poor correlations were observed in the cytotoxicity between TIL and PBM, SPC, or LNC. Phenotypic analysis of each cell population was performed before and after activation with IL 2. Before culture, the cells mediating natural killer (NK) activity such as CD16+, CD56+, and CD57+ cells were few in LNC and TIL. However, CD56+ and CD57+ cells in TIL were increased after culture. Then, CD4+Leu8+ and CD8+CD11+ cells, which identify suppressor cell function, were not elevated in LNC or TIL, as compared to that in PBM or SPC. Further, the proportions of OKIa1+ and CD25+ cells expressing T-cell activation and IL 2 receptor were uniformly increased in all cell populations after culture. These results indicate the differential reactivity of each lymphocyte population to IL 2 and fundamental dysfunction of LNC and, especially TIL, suggesting the specific influence of the local tumor environment on the lymphocyte function in the area in patients with gastric carcinoma.

Entities:  

Mesh:

Year:  1994        PMID: 8176929     DOI: 10.1002/jso.2930550310

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

1.  An acidic microenvironment impairs the generation of non-major histocompatibility complex-restricted killer cells.

Authors:  B Müller; B Fischer; W Kreutz
Journal:  Immunology       Date:  2000-03       Impact factor: 7.397

2.  PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients.

Authors:  Junji Akagi; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2010-03-13       Impact factor: 3.402

3.  Origin of CD57+ T cells which increase at tumour sites in patients with colorectal cancer.

Authors:  T Okada; T Iiai; Y Kawachi; T Moroda; Y Takii; K Hatakeyama; T Abo
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

4.  Prognostic value of CD57(+) T lymphocytes in the peripheral blood of patients with advanced gastric cancer.

Authors:  Junji Akagi; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

5.  Spontaneous antibody-secreting cells in the stomach of gastric cancer patients.

Authors:  T Kunori; F Shinya; T Satomi; J Itoh; M Abe; M Takahashi; T Yokota; Y Abe; K Hiraoka; S Kawaguchi; I Tanaka; M Mochizuki; S Asano
Journal:  J Gastroenterol       Date:  1996-04       Impact factor: 7.527

6.  IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity.

Authors:  I Kryczek; M Gryboś; L Karabon; A Klimczak; A Lange
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

7.  Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer.

Authors:  N Chaput; M Svrcek; A Aupérin; C Locher; F Drusch; D Malka; J Taïeb; D Goéré; M Ducreux; V Boige
Journal:  Br J Cancer       Date:  2013-07-18       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.